普萊柯(603566.SH):獲得新獸藥註冊證書 將為公司帶來新的業績增長點
格隆匯5月20日丨普萊柯(603566.SH)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准普萊柯生物工程股份有限公司(以下簡稱“公司”)和子公司洛陽惠中生物技術有限公司申報的“雞新城疫、傳染性支氣管炎、禽流感(H9亞型)三聯滅活疫苗(N7a株+M41株+SZ株)”為新獸藥,農業農村部於2020年5月19日公示了核發《新獸藥註冊證書》(農業農村部公告第299號)事項。
該產品於2016年2月1日向農業農村部提交臨牀試驗申請,經後續臨牀試驗、新獸藥註冊等階段,農業農村部於2020年5月19日公告核發新獸藥註冊證書。截至目前,該產品開發累計投入研發費用434.52萬元。
該新獸藥證書的取得是公司持續重視科技創新、加大研發投入的結果,進一步體現了公司的創新實力,同時也推動了禽用疫苗產品的升級換代,與公司其他系列基因工程禽用疫苗構建強大的產品技術壁壘,有效提升了公司在行業內的競爭力,將為公司帶來新的業績增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.